Related Experiment Video
Updated: Nov 19, 2025
Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles
Neazar E Baghdadi1, Benjamin P Burke2, Tahani Alresheedi3
1Centre of Nanotechnology, King Abdul-Aziz University, Jeddah, Saudi Arabia and Department of Chemistry, University of Hull, Cottingham Road, Hull, HU6 7RX, UK. s.j.archibald@hull.ac.uk.
Abstract:
The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.
Insights
Researchers developed novel iron oxide nanoparticles targeting the CXCR4 receptor for cancer applications. These nanoparticles demonstrated high affinity and effectively inhibited receptor binding, showing promise for diagnostics and therapeutics.
Area of Science:
- Biomolecular target identification
- Nanotechnology in medicine
- Cancer research
Background:
- The CXCR4 chemokine receptor is a key target in cancer diagnostics and therapeutics.
- Developing targeted nanomedicines requires effective strategies for receptor binding.
Purpose of the Study:
- To create a multivalent nanoparticle system for targeting the CXCR4 receptor.
- To evaluate the binding affinity and inhibitory potential of the developed nanostructures.
Main Methods:
- Conjugating iron oxide nanoparticles with multiple low-affinity azamacrocyclic CXCR4 antagonists.
- Coating the nanostructures with silica for stability.
- Assessing particle size, suspension stability, and CXCR4 binding affinity.
- Performing receptor binding competition assays using anti-CXCR4 mAb on Jurkat cells.
Main Results:
- The silica-coated nanostructures exhibited good suspension stability and a mode size of 72 nm.
- The multivalent nanoparticles displayed high affinity for CXCR4.
- Demonstrated >98% inhibition of anti-CXCR4 mAb binding in competition assays.
Conclusions:
- The developed multivalent iron oxide nanoparticles show significant potential as CXCR4-targeted agents.
- This approach offers a promising strategy for advancing cancer diagnostics and therapeutics.
More Related Videos
08:26Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles
Published on: October 19, 2015
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
